Image analysis as an adjunct to manual HER-2 immunohistochemical review: A diagnostic tool to standardize interpretation

Histopathology

Volumn 57, Issue 1, 2010, Pages 27-38

  Dobson, Lynne ^a   Conway, Catherine ^a   Hanley, Alan ^a   Johnson, Alex ^a   Costello, Sean ^a   O'Grady, Anthony ^a   Connolly, Yvonne ^b   Magee, Hilary ^b   O'Shea, Daniel ^a   Jeffers, Michael ^b   Kay, Elaine ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

fluorescence in situ hybridization; HER 2; image analysis; immunohistochemistry; virtual slides

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TRASTUZUMAB; TUMOR MARKER;

ALGORITHM; ARTICLE; CLASSIFICATION; COMPUTER ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; RELIABILITY; STANDARDIZATION; BREAST NEOPLASMS; CHEMISTRY; COHORT ANALYSIS; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; EVALUATION STUDY; FEMALE; GENETICS; IMAGE PROCESSING; PROCEDURES; PROTO ONCOGENE; STANDARDS;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COHORT STUDIES; DIAGNOSIS, COMPUTER-ASSISTED; FEMALE; GENES, ERBB-2; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 77954557383     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03577.x     Document Type: Article

References (40)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 235 177 182.
2. Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res. 2003 63 1445 1448.
3. Ellis CM, Dyson MJ, Stephenson TJ, Maltby EL. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J. Clin. Pathol. 2005 58 710 714.
4. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 244 707 712.
5. Lacroix-Triki M, Mathoulin-Pelissier S, Ghnassia JP et al. High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study. Eur. J. Cancer 2006 42 2946 2953.
6. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001 344 783 792.
7. Slamon D. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab (TCH) in HER2 positive early breast cancer patients.
8. Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J. Clin. Oncol. 2004 22 854 863.
9. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007 25 118 145.
10. Egervari K, Szollosi Z, Nemes Z. Tissue microarray technology in breast cancer HER2 diagnostics. Pathol. Res. Pract. 2007 203 169 177.
11. Walker RA, Bartlett JM, Dowsett M et al. HER2 testing in the UK: further update to recommendations. J. Clin. Pathol. 2008 61 818 824.
12. Dietel M, Ellis IO, Hofler H et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch. 2007 451 19 25.
13. Di Palma S, Collins N, Bilous M et al. A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer. J. Clin. Pathol. 2008 61 757 760.
14. Rhodes A, Jasani B, Anderson E, Dodson AR, Balaton AJ. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am. J. Clin. Pathol. 2002 118 408 417.
15. Thomson TA, Hayes MM, Spinelli JJ et al. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod. Pathol. 2001 14 1079 1086.
16. Ciampa A, Xu B, Ayata G et al. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system. Appl. Immunohistochem. Mol. Morphol. 2006 14 132 137.
17. Cregger M, Berger AJ, Rimm DL. Immunohistochemistry and quantitative analysis of protein expression. Arch. Pathol. Lab. Med. 2006 130 1026 1030.
18. Scheldermann D, Hyldebrandt T, Ejersbo D, Hoelund B. Automated screening versus manual screening: a comparison of the ThinPrep Imaging System and manual screening in a time study. Diagn. Cytopathol. 2007 35 348 352.
19. Conway C, Dobson L, O'Grady A, Kay E, Costello S, O'Shea D. Virtual microscopy as an enabler of automated/quantitative assessment of protein expression in TMAs. Histochem. Cell Biol. 2008 130 447 463.
20. Kay EW, Walsh CJ, Cassidy M, Curran B, Leader M. C-erbB-2 immunostaining: problems with interpretation. J. Clin. Pathol. 1994 47 816 822.
21. Paik S, Bryant J, Tan-Chiu E et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J. Natl. Cancer Inst. 2002 94 852 854.
22. Roche PC, Suman VJ, Jenkins RB et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J. Natl. Cancer Inst. 2002 94 855 857.
23. Press MF, Sauter G, Bernstein L et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin. Cancer Res. 2005 11 6598 6607.
24. Hicks DG, Kulkarni S. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am. J. Clin. Pathol. 2008 129 263 273.
25. Hsi ED, Tubbs RR. Guidelines for HER2 testing in the UK. J. Clin. Pathol. 2004 57 241 242.
26. Mulrane L, Rexhepaj E, Penney S, Callanan JJ, Gallagher WM. Automated image analysis in histopathology: a valuable tool in medical diagnostics. Expert Rev. Mol. Diagn. 2008 8 707 725.
27. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977 33 159 174.
28. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007 25 5287 5312. (Pubitemid 350232263)
29. Tawfik OW, Kimler BF, Davis M et al. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology 2006 48 258 267.
30. Wang S, Saboorian MH, Frenkel EP et al. Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am. J. Clin. Pathol. 2001 116 495 503.
31. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 2005 5 845 856.
32. Marrer E, Dieterle F. Biomarkers in oncology drug development: rescuers or troublemakers? Expert Opin. Drug Metab. Toxicol. 2008 4 1391 1402.
33. Mulrane L, Rexhepaj E, Smart V et al. Creation of a digital slide and tissue microarray resource from a multi-institutional predictive toxicology study in the rat: an initial report from the PredTox group. Exp. Toxicol. Pathol. 2008 60 235 245.
34. Divito KA, Berger AJ, Camp RL, Dolled-Filhart M, Rimm DL, Kluger HM. Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Cancer Res. 2004 64 8773 8777.
35. Gokhale S, Rosen D, Sneige N et al. Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl. Immunohistochem. Mol. Morphol. 2007 15 451 455.
36. Rexhepaj E, Brennan DJ, Holloway P et al. Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res. 2008 10 R89.
37. Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res. 2006 66 5487 5494.
38. Harigopal M, Berger AJ, Camp RL, Rimm DL, Kluger HM. Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer. Clin. Cancer Res. 2005 11 4083 4089.
39. Rhodes A, Borthwick D, Sykes R, Al-Sam S, Paradiso A. The use of cell line standards to reduce HER-2/neu assay variation in multiple European cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to trastuzumab. Am. J. Clin. Pathol. 2004 122 51 60.
40. Dowsett M, Hanna WM, Kockx M et al. Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod. Pathol. 2007 20 584 591.